Molecular testing by targeted NGS revealed clinically significant amplifications of MYC and CCND2 genes, as well as three alterations involving frequently implicated genes in HR-positive breast cancer: PIK3CA, TP53, and GATA3 (8). This evidence concerns the gene CCND2 and breast cancer.